What is the recommended enoxaparin (Clexane) dosing regimen for an adult with acute ST‑segment‑elevation myocardial infarction undergoing fibrinolysis or primary percutaneous coronary intervention, including renal‑function adjustments and treatment duration?

Enoxaparin (Clexane) in ST-Elevation Myocardial Infarction

For STEMI patients undergoing fibrinolysis, enoxaparin is superior to unfractionated heparin and should be administered as a 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours for up to 8 days or until hospital discharge, with dose reduction to 1 mg/kg once daily in patients with creatinine clearance <30 mL/min. 1, 2, 3

Fibrinolytic Strategy (When Primary PCI Cannot Be Performed Within 120 Minutes)

Standard Dosing Regimen

• Administer 30 mg IV bolus immediately before or with fibrinolytic therapy 1
• Follow with 1 mg/kg subcutaneously every 12 hours starting 15 minutes after the IV bolus 1, 3
• Continue for the duration of hospitalization up to 8 days 1
• This regimen reduced death or recurrent MI by 17% compared to unfractionated heparin (9.9% vs 12.0%, P<0.001) and reduced nonfatal reinfarction by 33% (3.0% vs 4.5%, P<0.001) 3

Renal Function Adjustments

• Creatinine clearance ≥30 mL/min: Standard dose of 1 mg/kg subcutaneously every 12 hours 1, 2
• Creatinine clearance <30 mL/min: Reduce to 1 mg/kg subcutaneously once daily 1, 2
• No aPTT monitoring is required, unlike unfractionated heparin 1, 4

Age-Related Cautions

• Patients ≥75 years: Exercise particular caution due to increased intracranial hemorrhage risk observed in prehospital administration studies 1
• The ASSENT-3 PLUS trial showed excess intracranial bleeding exclusively in elderly patients when enoxaparin was given prehospitally 1
• However, the ExTRACT-TIMI 25 trial demonstrated net clinical benefit across all age groups when administered in-hospital 3

Primary PCI Strategy (When PCI Can Be Performed Within 120 Minutes)

Anticoagulation Approach

• Unfractionated heparin remains the preferred anticoagulant for primary PCI as a weight-adjusted IV bolus followed by infusion 1, 2
• Enoxaparin is an acceptable alternative for primary PCI, though less extensively studied in this setting 1, 2
• If enoxaparin is chosen for primary PCI: administer 0.5 mg/kg IV bolus followed by 1 mg/kg subcutaneously 5
• Fondaparinux must not be used as the sole anticoagulant for primary PCI (Class III: Harm) 1, 2

Seamless Transition After Fibrinolysis

• If a patient receives enoxaparin with fibrinolysis and then undergoes PCI, continue the same enoxaparin regimen without switching to another anticoagulant 6
• This seamless strategy reduced death or recurrent MI to 10.7% versus 13.8% with unfractionated heparin (P<0.001) among patients who underwent PCI after fibrinolysis 6
• No additional anticoagulant is needed in the catheterization laboratory when enoxaparin is already on board 6

Timing of Angiography After Fibrinolysis

• Transfer immediately to a PCI-capable center after fibrinolysis, regardless of apparent reperfusion success 1, 2
• Perform angiography and PCI of the infarct-related artery between 2–24 hours after successful fibrinolysis 1, 2
• Rescue PCI is indicated immediately if fibrinolysis fails (defined as <50% ST-segment resolution at 60–90 minutes) 1, 2
• Emergency angiography at any time for hemodynamic instability, electrical instability, heart failure, shock, or worsening ischemia 1, 2

Bleeding Risk and Safety Profile

Expected Bleeding Rates

• Major bleeding occurs in approximately 2.1% of patients receiving enoxaparin versus 1.4% with unfractionated heparin (P<0.001) 3
• Minor bleeding is more common with enoxaparin but does not offset the mortality and reinfarction benefits 3, 4
• The composite of death, reinfarction, or intracranial hemorrhage (net clinical benefit) favored enoxaparin: 10.1% versus 12.2% with unfractionated heparin (P<0.001) 3

Critical Contraindications

• Active bleeding or high bleeding risk conditions 1
• Severe uncontrolled hypertension (systolic >180 mmHg or diastolic >110 mmHg) until blood pressure is controlled 2
• Recent intracranial hemorrhage, stroke within 3 months, or known intracranial pathology 2

Practical Advantages Over Unfractionated Heparin

• No aPTT monitoring required, simplifying management and reducing nursing burden 1, 4
• More predictable pharmacokinetics with consistent anti-Xa activity throughout treatment 1, 4
• Lower rate of thrombocytopenia compared to unfractionated heparin 1
• Reduced recurrent ischemia: 18.8% versus 40.6% in comparative studies (P=0.055) 7
• Subcutaneous administration allows continuation outside the intensive care setting 4

Concomitant Antiplatelet Therapy

• Aspirin (oral or IV) must be given immediately at the time of fibrinolysis 1, 2
• Add clopidogrel as the P2Y12 inhibitor when fibrinolysis is the reperfusion strategy 1, 2
• For primary PCI, use prasugrel or ticagrelor (preferred over clopidogrel) before or at the time of PCI 1, 2
• Continue dual antiplatelet therapy for 12 months unless excessive bleeding risk 1